Disease Overview：Hereditary Hemorrhagic Telangiectasia（HHT）
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is an autosomal dominant genetic disorder characterized by abnormal blood vessel formation—specifically arteriovenous malformations (AVMs) and telangiectasias—in mucocutaneous tissues and vital organs including the lungs, brain, liver, and gastrointestinal tract. Clinical manifestations commonly include recurrent epistaxis, mucocutaneous telangiectasias, and potentially life-threatening complications such as cerebral or pulmonary hemorrhage, high-output heart failure, or stroke due to paradoxical embolism. Diagnosis relies on the Curaçao criteria and confirmed through genetic testing for mutations in *ENG*, *ACVRL1*, or *SMAD4*. Management is multidisciplinary, involving surveillance imaging (contrast-enhanced CT/MRI), endovascular embolization for pulmonary or cerebral AVMs, laser ablation or septodermoplasty for epistaxis, and iron replacement for chronic anemia.
China offers distinct advantages for HHT care: leading academic hospitals—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—host dedicated vascular anomaly centers with internationally trained hematologists and interventional radiologists. Advanced capabilities include 3T MRI angiography, cone-beam CT-guided embolization, and next-generation sequencing for genotype–phenotype correlation. Over 200 documented HHT cases have been successfully managed annually across Tier-1 centers, with published five-year complication-free survival exceeding 92% for treated pulmonary AVMs. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising clinical standards or regulatory oversight (NMPA-approved devices, ISO-certified protocols). As a specialized medical tourism agency, we facilitate seamless international patient journeys—from pre-travel eligibility assessment and hospital referral to visa support, real-time interpreter services, transparent itemized pricing, and post-treatment follow-up coordination—ensuring continuity of care and financial predictability.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Hereditary Hemorrhagic Telangiectasia (HHT)
Non-Surgical / Conservative / Medication Options
*Target criteria:* Mild epistaxis, low AVM burden, asymptomatic screening, or contraindication to intervention.
- •Tranexamic Acid (oral)
- *30-day supply:* $18–$24 (generic, Grade 3A hospital pharmacy)
- •Topical Bevacizumab (intranasal gel, off-label)
- •Iron supplementation + IV iron (for chronic anemia)
- *Pre-infusion labs (CBC, ferritin, CRP, renal panel):* $42–$58
- •Annual surveillance package (mandatory for all diagnosed patients)
- *Abdominal MRI (liver AVM assessment):* $275–$330 - *CBC + coagulation panel + VWF antigen:* $38–$52
Surgical / Procedural / Interventional Options
*Eligibility:* Confirmed pulmonary/liver/brain AVM ≥3 mm; recurrent epistaxis refractory to medical therapy; hemoglobin <10 g/dL with documented AVM-related shunting.
- •Pulmonary AVM Embolization (coils/microspheres)
- *Pre-op workup (ECG, ABG, contrast-enhanced CT, echocardiogram with bubble study):* $210–$285
- •Endoscopic Nasal Cauterization + Septodermoplasty
- *Pre-op labs (PT/INR, platelets, type & screen):* $28–$40
- •Liver AVM Embolization (selective, non-curative)
- *Pre-op hepatic venous pressure gradient (HVPG) + MR elastography:* $340–$425
Special / Complex Condition Management
- •High-output heart failure due to diffuse hepatic AVMs:
- *Bridge therapy (IV bevacizumab 5 mg/kg q2w × 3 doses):* $2,650–$3,100
- •Cerebral AVM resection/radiosurgery (neurosurgery referral only):
- *Craniotomy + intraoperative angiography:* $8,700–$10,500
Quick Selection Guide
- •Children (<12 years), mild epistaxis: Start with tranexamic acid + annual CT ($18–$24 + $185–$220). Avoid embolization unless life-threatening PAVM.
- •Adults, moderate PAVMs (1–2 lesions, SpO₂ <92%): First-line pulmonary embolization ($3,200–$4,100); cost-effective vs. lifelong transfusion.
- •Elderly (>75), comorbid CHF/COPD: Conservative management (topical bevacizumab + IV iron) — avoids procedural risk; total monthly cost: $140–$190.
- •Young adults with diffuse hepatic AVM + cardiac decompensation: Expedited liver transplant evaluation ($1,950–$2,400); bridge with IV bevacizumab if transplant delayed.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Hereditary Hemorrhagic Telangiectasia Medical Vacation Packages
Curated transparent all-inclusive packages combining Hereditary Hemorrhagic Telangiectasia treatment with China top medical destinations:
